Navigation Links
Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology
Date:6/11/2008

SEATTLE and PARIS, June 12 /PRNewswire-FirstCall/ -- Targeted Genetics Corporation (Nasdaq: TGEN) announced today that positive results of a Phase 1/2 clinical study demonstrate that tgAAC94, its investigational agent designed to inhibit activity of tumor necrosis factor-alpha (TNF-alpha), a key mediator of inflammation, is well tolerated and may improve disease symptoms in inflammatory arthritis patients refractory to other therapies, including systemic TNF antagonists. Full results of the study were presented here today during an oral presentation at the Annual European Congress of Rheumatology (EULAR).

The Phase 1/2 study evaluated multiple doses of tgAAC94 administered directly to affected joints with or without concurrent systemic TNF antagonist therapies. The study achieved its primary endpoint of safety and tolerability.

"We are encouraged by the patient-reported symptom improvement -- early signs of efficacy that indicate further study is warranted," said Philip Mease, M.D., Chief, Rheumatology Clinical Research Division of Swedish Hospital Medical Center and Head of Seattle Rheumatology Associates, who presented the data.

Study Details

127 patients with inflammatory arthritis received a single intra-articular injection of either tgAAC94 or placebo, followed by a second injection 12-30 weeks later depending on when the injected joint met criteria for re-injection. tgAAC94 was well tolerated at all dose levels. Two SAEs of focused interest were reported -- a culture-negative septic arthritis considered probably related to study drug and a fatal disseminated histoplasmosis and retroperitoneal hemorrhage considered not related to study agent. Administration site reactions were observed in 12% of subjects.
'/>"/>

SOURCE Targeted Genetics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkins Lymphoma
2. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
3. Genomic Health Announces Results of Initial Studies to Develop Predictive Tests for Targeted Therapies
4. Phase I/II Study of Targeted Gene Delivery In Vivo - Intravenous Infusions of REXIN-G - Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Patients With Progressive Chemo-Resistant Bone and Soft Tissue Sarcoma (ASCO 2008)
5. TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in Cancerous Lesions (ASCO 2008)
6. TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity Without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)
7. Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib)
8. Phosphagenics Reports Positive Pre-clinical Results for Targeted Delivery of Lidocaine
9. Semafores PI3 Kinase Inhibitor SF1126 is a Vascular Targeted Conjugate in Phase I Clinical Trials in Solid Tumors and Multiple Myeloma
10. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
11. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015 The role of ... decade but one thing hasn,t changed: face-to-face meetings are ... relationships with Key Opinion Leaders. Yet at ... most valuable type of interaction, field medical teams within ... KOL interactions. This is just one of the challenges ...
(Date:2/27/2015)...  Following a bipartisan vote in the House ... the Medicare DMEPOS Competitive Bidding Improvement Act of ... released a statement praising the Committee,s work and ... "Today,s mark-up of the Competitive Bidding ... Committee is a critical step forward for this ...
(Date:2/27/2015)... , Feb. 27, 2015 An aggressive campaign ... cut the rate of infection with a dangerous drug-resistant ... Clostridium difficile, or C.diff, is a bacterium ... inflammation of the colon. A recent article in the ... difficile Infection in the United States ...
Breaking Medicine Technology:Improving the Management of MSL Teams to Create Value across a Diverse Set of Customers 2Bidding Fix Takes Major Step Forward After Bipartisan Vote of House Ways and Means Committee 2Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 2Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 3
... May 15, 2012 Millennium Surgical Corp. continues to ... activity increased in the third quarter of 2011 and ... of new clients for the first four months of ... FY2011. To accommodate additional clients and the increasing number ...
... -- Global Information Inc. is pleased to announce ... Contract Research Organizations Market to 2018 The ... 12% from 2009 to 2010 according to GBI Research,s ... to 2018 : Public-Private Partnerships to Strengthen Research Capacities ...
Cached Medicine Technology:Millennium Surgical Corp. Announces Sales Figures, Growth 2Contract Research Organizations Set to Experience Rapid Growth as Development Costs for New Drugs Continue to Rise 2
(Date:2/28/2015)... The Heart Fit Clinic started doing External ... machine. The Heart Fit Clinic is also selling the ... model. The goal is to scale the business to ... buy External Counterpulsation machines can be difficult ... this process and achieve the desired results. , ...
(Date:2/28/2015)... Indosoft Inc , developers of Q-Suite, a ... to announce the development of Q-Suite 5.9. Building off ... Q-Suite, this new version will include enhancements to existing ... to the leading edge call center software. General availability ... features to enhance security and protection. Administrators will be ...
(Date:2/28/2015)... St. Louis, MO (PRWEB) February 28, 2015 ... a leading provider of outsourced sales, marketing and ... announces their client, BIOTA Botanicals, is bringing its ... , Celebrated worldwide, BIOTA Botanicals’ products are specifically ... the herbal care experts, BIOTA is committed to ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 How ... Supportive? Strategic? , There are all kinds of ... To raise awareness of the advantages and applications ... PeopleKeys is launching a new product this spring ... better understand the connection between personality type, leadership, ...
(Date:2/28/2015)... 2015 Javon Bea Mercy Health ... Hospital as stroke capable by the State of Illinois, ... to Mercy Harvard Hospital. , The hospital was required ... ability to treat stroke according to national standards of ... stroke patients to bypass hospitals not designated as an ...
Breaking Medicine News(10 mins):Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3Health News:PeopleKeys Launches The Leadership Report 2Health News:PeopleKeys Launches The Leadership Report 3Health News:Mercy Harvard Hospital Recognized as Leader in Stroke Care - Javon Bea 2
... VAXINE Pty Ltd, a South Australian biotechnology company, has ... swine flu vaccine. , , ... administration to human subjects of a swine flu vaccine anywhere ... "The swine influenza vaccine we are testing, unlike old-fashioned egg-based ...
... HILLS, Mass., July 22 Joseph F. Finn, Jr., C.P.A. ... have been assigned to him for the benefit of EPIX,s ... and services focus on the discovery and development of novel ... in silico drug discovery platform. The company ...
... DOYLESTOWN, Pa., July 22 Quigley Pharma Inc., a wholly-owned ... www.quigleyco.com , today announced the ... compound QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. ... with the final and comprehensive conclusions revealing that (i) the ...
... , , , ... Inc. (OTC Bulletin Board: TCSR), which develops, manages and owns ... six-month extension of its construction/mini-perm loan with Trustmark National Bank. ... senior living facility in Port Lavaca, Texas, Trustmark National ...
... nutrition expert says, , WEDNESDAY, July 22 (HealthDay News) -- ... the kind of snack that matters, but who eats it. ... non-obese women, the healthy-weight women wanted less of the treat ... and non-obese women respond to high-energy, high-density snacks in different ...
... , , ... of the world,s leading research and advisory firms focusing on ... Bristol-Myers Squibb,s Orencia is low among rheumatoid arthritis agents. Rheumatologists ... necrosis factor-alpha (TNF-alpha) inhibitors across the top drivers of perception ...
Cached Medicine News:Health News:Vaxine Wins Line Honours With World's First Human Swine Flu Vaccine 2Health News:EPIX Pharmaceuticals, Inc. Assigns all Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors 2Health News:Quigley Corporation Announces Final Results of Quigley Pharma's Phase IIb Study 2Health News:Quigley Corporation Announces Final Results of Quigley Pharma's Phase IIb Study 3Health News:Quigley Corporation Announces Final Results of Quigley Pharma's Phase IIb Study 4Health News:Quigley Corporation Announces Final Results of Quigley Pharma's Phase IIb Study 5Health News:TrinityCare Senior Living Announces Extension of Financing for Trinity Shores Facility in Port Lavaca, Texas 2Health News:TrinityCare Senior Living Announces Extension of Financing for Trinity Shores Facility in Port Lavaca, Texas 3Health News:Eating Habits in the Obese May Echo Drug Addicts' Patterns 2Health News:Eating Habits in the Obese May Echo Drug Addicts' Patterns 3Health News:For Treatment of Rheumatoid Arthritis, Surveyed Rheumatologists and Patients Differ In Their Perception of Bristol-Myers Squibb's Orencia 2Health News:For Treatment of Rheumatoid Arthritis, Surveyed Rheumatologists and Patients Differ In Their Perception of Bristol-Myers Squibb's Orencia 3
FREEDOM® Memory Thumb Spica lets you make a custom splint in minutes. Immerese in 160 F water until pliable, and remove. Amazingly, it maintains its shape and is ready to be precisely, profession...
... Freedom® CMC ThumbFit™ reduces joint instability ... splint is remarkably comfortable and easy ... Kirby, OTR/L, CHT and Robert V. ... splint together in response to patients' ...
... offers thumb and wrist control in a ... Lightweight stays provide firm control at the ... contoured for proper positioning and fit. Ideal ... CMC joint arthritis, and following cast removal. ...
... Soft, foam-lined FoamWrap ThumWrap Splints offer support ... Ideal to relieve mild pain or strain ... activities. Choose either the rigid or the ... amount of support. Washable and breathable, the ...
Medicine Products: